Abbreviated Key Title: Sch Acad J Pharm ISSN 2347-9531 (Print) | ISSN 2320-4206 (Online) Journal homepage: http://saspublisher.com/sajp/

Pharmaceutical Chemistry

An Overview of Chemistry and Antitubercular Activity of Thiazolidinediones

Harish Ratnaparkhi¹, Snehal Thakar², Deepali Bansode^{3*}

DOI: 10.36347/sajp.2020.v09i01.006 | **Received:** 08.01.2020 | **Accepted:** 15.01.2020 | **Published:** 22.01.2020

*Corresponding author: Dr. (Mrs.) Deepali Amol Bansode

Abstract Original Research Article

Thiazolidinediones (TZDs) constitute an important class of heterocyclic compounds which possess significant antitubercular activity along with various other activities like antimicrobial, anti-HIV, anti-inflammatory, antioxidant and anticonvulsant. Tuberculosis is serious health complication in which multidrug-resistance is challenging problem in treatment of tuberculosis. In the proposed article, we have shown new methods of synthesis of thiazolidinediones and antitubercular activity of the synthesized compounds. Various substituents (electron donating as well as withdrawing) like –methoxy, -chloro, -flouro, -nitro, -hydroxy are attached at different positions on different aliphatic and aromatic substitutions of thiazolidinedione ring amongst them, the compounds possessing electron withdrawing groups on substitutions have shown enhancement in the antitubercular activity.

Keywords: Thiazolidinediones, Synthesis, PPAR_Y Ligand, Biological activities, Glitazones.

Copyright @ 2020: This is an open-access article distributed under the terms of the Creative Commons Attribution license which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use (NonCommercial, or CC-BY-NC) provided the original author and source are credited.

ABBREVIATIONS

TB- Tuberculosis

HIV- Human Immunodeficiency Virus

MDRTB- Multidrug Resistant Tuberculosis

M. tuberculosis- Mycobacterium tuberculosis

MIC- Minimum Inhibitory Concentration

PPAR- Peroxisome proliferator-activated receptor gamma

MGIT- Mycobacteria growth incubator tube

Introduction

Thiazolidine-2, 4-diones (Fig.1) are sulphur and nitrogen containing pentacyclic compound, also known as glitazones. After the prototypical drug ciglitazone, the new class of heterocyclic compounds consisting of a five membered thiazolidine nucleus which is present in numerous biological activities like antimicrobial antidiabetic [1-3],[4-6],inflammatory [6-7], anti-HIV [8], antioxidant [9] and anticonvulsant [10]. Thiazolidine-2, 4-diones are wellknown pharmacophores introduced in the late 1990's for the treatment of diabetes mellitus. These are five membered heterocyclic molecules which having thiazole nucleus with two carbonyl functional group at second and fourth carbon.

$$0 \xrightarrow{3 \text{ N}} 2 \text{ O}$$

Fig-1: Chemical structure of 2, 4-thiazolidinedione

Tuberculosis is one of the top causes of death worldwide, caused by bacteria *Mycobacterium tuberculosis*. It is curable disease but multidrugresistant TB (MDR-TB) remains a public health crisis and a health security threat. WHO estimates that there were 558000 new cases with resistance to rifampicinthe most effective first-line drug, of which 82% had MDR-TB. Therefore, several new 2,4-thiazolidinediones have been synthesized and screened for their antitubercular activity against *M. tuberculosis*

¹Research Scholar, Department of Pharmaceutical Chemistry, Bharati Vidyapeeth (Deemed to be University), Poona College of Pharmacy, Kothrud, Pune-411038, Maharashtra, India

²Research Scholar, Department of Pharmaceutical Chemistry, Bharati Vidyapeeth (Deemed to be University), Poona College of Pharmacy, Kothrud, Pune-411038, Maharashtra, India

³Associate Professor, Department of Pharmaceutical Chemistry, Bharati Vidyapeeth (Deemed to be University), Poona College of Pharmacy, Kothrud, Pune-411038, Maharashtra, India

H37Rv strain have shown promising results indicating the potential of this scaffold in the development of novel anti-TB agents [11-12].

Thiazolidine-2, 4-dione scaffold is found to exhibit a significant antitubercular activity these findings attracted scientists to synthesize the thiazolidinedione derivatives and evaluated for their pharmacological activities. We could not find any

review concerning about the new methods for synthesis of recently developed thiazolidinedione derivatives with their antitubercular activity. Therefore, this article attempts to review the new methods for the synthesis of thiazolidinediones along with their improved potential for treating tuberculosis. Compounds synthesized using the given synthetic strategies gives us a diversity of compounds with varying complexity and biological relevance.

Fig-2: Marketed drugs containing 2, 4-thizolidinedione

Physical and chemical properties of 2, 4-thiazolidinedione

Thiazolidine-2, 4-dione is a white crystalline powder, sparingly soluble in water, methanol, ethanol,

dimethylsulfoxide and ethyl ether. It has melting point of 123-125°C. Summary of it's physical and chemical properties is depicted in Table 1 [13].

Table-1: Physical and chemical properties of 2, 4-thiazolidinedione

Sr. no.	Parameters	Inference	
1.	Appearance	White needle like crystals.	
2.	IUPAC name	1,3-thiazolidine-2,4-dione	
3.	Molecular formula	$C_3H_3NO_2S$	
4.	Molecular Weight	117.13 g/mol	
5.	Melting point	123-125°C	
6.	Boiling point	178-179°C	
7.	Density	1.408	
8.	Refractive index	1.513	
9.	Solubility	Water, methanol, dimethylsulfoxide, ethanol, and ethyl ether.	
10.	Log P	-0.031	
11.	Storage	Store below +30°C.	
12.	Thin layer chromatography	R _f value- 0.6	
		[Mobile phase- Chloroform: Methanol (4.5:0.5; v/v)]	

Structural characterization of 2, 4-thiazolidinedione

The 2,4-thiazolidinedione can be structurally characterized by using Infra-red spectroscopy which shows peaks for secondary amine at 3387cm⁻¹ (N-H Stretch), Carbonyl group at 1687cm⁻¹ (C=O Stretch), C-S at 622cm⁻¹ (Stretch) and by using Mass spectroscopy

which gives mass fragment at ESI⁺-117.01 [M+H]⁺. The Proton NMR at 400 MHz in DMSO-d6 shows peaks at 12.50 for one hydrogen of N-H and 4.39 for two hydrogens of -CH₂-. Summary of the characterization tools are depicted in Table 2 [14].

Table-2: Structural characterization of 2,4-thiazolidinedione

Sr. No.	Parameter	Inference	
1.	IR spectral data (KBr)	Functional group	Wavelength (cm ⁻¹)
		Secondary amine N-H Stretch	3387
		Carbonyl C=O Stretch	1687
		C-S Stretch	622
2.	Mass spectral data	ESI ⁺ - 117.01 [M+H] ⁺	
3.	¹ H-Nuclear Magnetic Resonance spectral data	12.50 (1H; S; NH), 4.39 (2H; S; CH ₂)	
	(Dimethylsulfoxide-d6, 400 MHz)		

Mechanism of action 2, 4-thiazolidinedione

Thiazolidinediones are synthetic ligands for the PPAR_Y (peroxisome proliferator-activated receptor gamma) receptors. In the cell, PPAR_Y forms a heterodimer with the retinoid X receptor (RXR). When induced by 2,4-thiazolidinediones, a conformational change occurs in the heterodimer and co-repressor complexes, this promotes binding of the PPAR_Y-RXR complex to PPAR_Y response elements (PPRE) in target genes and alteration of the transcription of these genes. PPREs are found in a number of genes involved in lipid metabolism and energy balance, including those encoding for lipoprotein lipase, fatty acid transporter protein, adipocyte fatty acid binding protein, fatty acyl CoA synthase, malic enzyme, glucokinase and the GLUT4 glucose transporter [15-17].

Methods of synthesis and antitubercular activity of 2, 4-thiazolidinedione

The 2, 4-thiazolidinediones have been synthesized by using conventional, solid phase and microwave assisted methods. The derivatives were

screened for their antitubercular activity against *M. tuberculosis* H37Rv strain by using different methods like Middlebrook 7H9 agar medium, BACTEC mycobacteria growth incubator tube system, Lowenstein Jensen and Microplate alamar blue assay (MABA) method.

CONVENTIONAL METHOD

2, 4-thiazolidinediones with substituted benzylidine ring

Pattan *et al.* [18] synthesized benzylidene-2,4-thiazolidinedione derivatives from chloroacetic acid and thiourea by using scheme 1 and 2, derivatives were screened for antitubercular activity by Middlebrook 7H9 agar medium against *M. tuberculosis* H37RV strain using streptomycin as standard drug which showed sensitivity at MIC value (25-100 μg/mL). The derivatives synthesized by scheme 1 and 2, the N-methylisonicotinamide substituted derivatives showed sensitivity at MIC values (50 and 100 μg/mL).

Cl S Conc.HCl
$$H_2O$$
 H_2O H_3CO H_3CO

Scheme-1: Synthesis of 4-chloroacetyl-benzylidene-2, 4-thiazolidinedione derivatives

CI—O +
$$\frac{S}{H_2O}$$
 $\frac{Conc.HCl}{H_2O}$ $\frac{H}{N}$ $\frac{Conc.HCl}{N}$ $\frac{H_3CO}{N}$ $\frac{H_3CO}{N}$ $\frac{H_3CO}{N}$ $\frac{H_3CO}{N}$ $\frac{H_3CO}{N}$ $\frac{(Z)-5-(4-methoxybenzylidene)-3-substitutedmethylthiazolidine-2,4-dione}$

Scheme-2: Synthesis of (Z)-5-(4-methoxybenzylidine)-3-substituted methylthiazolidine-2,4-diones

Thiazolyl benzenesulfonamide-condensed 2,4-thiazolidinediones

Parekh *et al.* [19] synthesized the 2, 4-thiazolidinedione derivatives containing

benzenesulfonamide by using chloroacetic acid, thourea and 4-phenylthiazol-2-amine as shown in scheme 3 and were screened for antitubercular activity using BACTEC MGIT system. Rifampicin (MIC value 40 μg/mL) and Isoniazid (MIC value 0.2 μg/mL) were used as standard drugs. Results revealed that final thiazolidinedione analogs possessing electron-donating group (-chloro) at C-2, C-3 and C-4 positions of the

phenyl ring displayed highest inhibition at a constant concentration level (MIC value 62.5 μ g/mL) against *M. tuberculosis* H37Rv strain.

Scheme-3: Synthesis of (Z)-4-((3-benzoyl-2,4-dioxothiazolidin-5-ylidene)methyl)-N-(4-substituted phenylthiazol-2-yl) benzene sulfonamides.

Dichlorobenzoylthiazolidine-2,4-diones containing substituted benzylidene ring

Shaikh *et al.* [20] prepared 2,4-thiazolidinedione derivatives possessing dichlorobenzoyl and substituted benzylidene ring by using Knoevenagel condensation reaction of 2,4-thiazolidinediones with aromatic aldehydes as shown in scheme 4, The synthesized compounds were screened against *M. tuberculosis* H37RV strain using rifampicin

as reference drug (MIC value 40 μ g/mL). Results revealed that 4-methoxy and 4-dimethylamino substituted compounds showed very good activity with MIC value (25-50 μ g/mL) and compounds having 3,4-dichlorobenzoyl, 4- methyl and 3,4,5- trimethoxy substitution showed comparable activity with MIC value (62.5-100 μ g/mL).

-N-(4-substitutedphenylthiazol-2-yl)benzenesulfonamide

Scheme-4: Synthesis of (Z)-5-substituted benzylidene-3-(3,4-dichlorobenzoyl)thiazolidine-2,4-dione

Thiazolidinediones incorporated with Pyridine and 1, 3, 4-Oxadiazole

The 2,4-thiazolidinediones with pyridine and 1,3,4-oxadiazole synthesized from (Z)-5-benzylidenethiazolidine-2,4-dione as shown in scheme 5 by Patel *et al.* [21] were investigated for antitubercular activity against *M. tuberculosis* H37Rv

strain. Rifampicin was used as reference drug (MIC value 40 $\mu g/mL$). The results show that compounds bearing 4-fluoro and 4-methoxy substitution was most active amongst the tested compounds with MIC value (50 $\mu g/mL$).

$$R = \frac{1}{\sqrt{N}} + \frac{\frac{1}{\sqrt{N}} + \frac{\frac{1}{\sqrt{N}} + \frac{1}{\sqrt{N}} + \frac{1}{\sqrt{N}} + \frac{\frac{1}{\sqrt{N}} + \frac{1}{\sqrt{N}} + \frac{1}{\sqrt$$

Scheme-5: Synthesis of (Z)-5-substituted benzylidene-3-((5-(2-(benzylthio) pyridin-3-yl)-1,3,4-oxadiazol-2-yl)methyl)thiazolidine-2,4-diones

Ethyl-pyridin-ethoxy-benzylidine conjugated 2, 4-thiazolidinediones

Patel *et al.* [22] synthesized 2,4-thiazolidinediones conjugated with ethyl-pyridinethoxy-benzylidine from 2-(5-ethylpyridin-2-yl)ethan-1-ol as depicted in scheme **6** and examined them for antimycobacterial activity against *M. tuberculosis* H37Rv strain using rifampicin as reference drug (MIC

value 40 μ g/mL). Results indicated that compounds containing N, 6-dimethylbenzo[d]thiazol-2-amine substitution showed better activity with MIC value (25 μ g/mL) and N, 5-dimethylthiazol-2-amine and N-methyl-5-nitrobenzo[d]thiazol-2-amine substituted compounds showed good activity with MIC value (50-62.5 μ g/mL).

yl)methyl)thiazolidine-2,4-dione

Scheme-6: Synthesis of (E)-5-((2E, 4E)-5-(2-(5-ethylpyridin-2-yl) ethoxy) hexa-2, 4-dien-1-ylidene)-3-(2-oxoproply) thiazolidine-2, 4-diones

Arylidene thiazolidine-2, 4-diones

Ponnuchamy *et al.* [23] synthesized arylidene thiazolidine2,4-diones from 2,4-thiazolidinedione and 2-bromo-1-cyclopropyl-2-(2-fluorophenyl)ethan-1-one as depicted in scheme 7 which were screened for their antimycobacterial activity against *M. tuberculosis*

H37Rv strain in high throughput screen using isoniazid as reference drug with EC_{50} value (0.18 μ M). Among the screened compounds, the compounds with substituted thiophene-2-carbaldehyde was found to be smost active having EC_{50} value (6 μ M).

Scheme-7: Synthesis of (Z)-5-(argiomethylene)-3-(2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl) thiazolidine-2,4-dione

2, 4-thiazolidinediones bearing 2-amino-6-thiocyanato benzothiazole derivatives

The 2,4-thiazolidinediones bearing 2-amino-6-thiocyanato benzothiazole were synthesized from aniline as depicted in scheme 8 by Shaikh *et al.* [24] which were screened against *M. tuberculosis* H37RV strain with reference drug rifampicin (MIC value 40

 μ g/mL). Results showed that 3,4,5-trimethoxy, 4-chloro and 3-bromo substituted compounds showed good activity with MIC value (25-50 μ g/mL) and compounds having 4-fluoro, 3-methoxy-4-hydroxyl, 4-methoxy and 4-dimethylamino substitution showed comparable activity with MIC value (62.5-100 μ g/mL).

$$\begin{array}{c} \text{NH}_2 \\ \text{CH}_3\text{COOH stirr at} \\ \text{0-5}^\circ\text{C 2-3hr} \\ \text{RT 16hr} \\ \text{aniline} \end{array} \\ \text{NC} \\ \begin{array}{c} \text{N} \\ \text{NC} \\ \text{N} \\ \text$$

(*E*)-2-(5-substitutedbenzylidene-2,4-dioxothiazolidin-3-yl)-N-(6-thiocyanatobenzo[d]thiazol-2-yl)acetamide

$Scheme - 8: Synthesis \ of \ (E) - 2 - (5 - substituted benzylidene - 2, 4 - dioxothiazolidin - 3 - yl) - N - (6 - thiocyana to benzo[d] thiazol - 2 - yl) \ acetamide - 2 - yl) - N - (6 - thiocyana to benzo[d] thiazol - 2 - yl) - (7 - thiocyana to benzo[d] thiazol - 2 - yl) - (7 - thiocyana to benzo[d] thiazol - 2 - yl) - (7 - thiocyana to benzo[d] thiazol - 2 - yl) - (7 - thiocyana to benzo[d] thiazol - 2 - yl) - (7 - thiocyana to benzo[d] thiazol - 2 - yl) - (7 - thiocyana to benzo[d] thiazol - 2 - yl) - (7 - thiocyana to benzo[d] thiazol - 2 - yl) - (7 - thiocyana to benzo[d] thiazol - 2 - yl) - (7 - thiocyana to benzo[d] thiazol - 2 - yl) - (7 - thiocyana to benzo[d] thiazol - 2 - yl) - (7 - thiocyana to$

Thiazolidinedione clubbed with Imidozolones

Khan *et al.* [25] synthesized 2,4-thiazolidinediones clubbed with imidozolones from benzoylglycine and benzaldehyde as depicted in scheme 9 and examined for antimycobacterial activity by using L. J. method by using rifampicin as reference drug which showed activity at MIC value (40 μg/mL). The

results indicates that compounds having 4-hydroxy, 3-methoxy and 5-nitro substituents on benzene showed better activity with MIC value (25 µg/mL) and compounds having unsubstituted thiophene, 4-hydroxy, 4-methoxy, and 2,5-dimethoxy substituents on benzene showed good activity with MIC value (50-62.5 µg/mL).

5-((*Z*)-4-(4-((*Z*)-substitutedbenzylidene)-5-oxo-2-phenyl -4,5-dihydro-1*H*-imidazol-1-yl)benzylidene)thiazolidine-2,4-dione


 $Scheme - 9: Synthesis \ of \ 5-((Z)-4-(4-((Z)-substituted benzylidene)-5-oxo-2-phenyl-4, \\ 5-dihydro-1 H-imidazol-1-yl) benzylidene) thiazolidine-2, \\ dione$

SOLID PHASE SYNTHESIS

Thiazolidinedione combined with Pyrimidine conjugates

Šlachtová *et al.* [26] demonstrated the solid phase synthesis of 2, 4-thiazolidinediones combined with pyrimidine conjugates from Wang resin as shown in scheme 10. Antimycobacterial activity of synthesized compounds was evaluated against *M. tuberculosis*

H37Rv strain (NCTC 7416) using isoniazid as standard drug which showed activity at MIC value (0.125 μ g/mL). The results indicate that thiazolidinedione that having (trifluoromethyl) benzene substitution showed the highest antitubercular activity against *M. tuberculosis* H37Rv strain with MIC value (256 μ g/mL).



Scheme-10: Solid phase synthesis of 5 and 7

Microwave assisted synthesis Thiazolidinedione with imidazo[2,1-b] [1,3,4] thiadiazole

The 2, 4-thiazolidinediones with imidazo [2,1-b] [1, 3, 4] thiadiazole were synthesized from 2,2,2-trifluoroacetic anhydride and hydrazinecarbothioamide as depicted in scheme 11 by Alegaon *et al.* [27] which were assessed for antitubercular activity against *M. tuberculosis* H37Rv strain (ATCC 27294) using the

Microplate Alamar Blue assay (MABA) method with standard drug, Isoniazid (MIC value 1.56 μ g/mL) and Rifampicin (MIC at 0.78 μ g/mL). The results of the antitubercular activity screening revealed that all compounds did not show any considerable activity except compound which is substituted with -chloro group showed antitubercular activity with MIC value (3.12 μ g/mL).

$$(CF_3CO)_2O + H_2N \xrightarrow{H} NH_2 \xrightarrow{O-5^\circ C \ 2 \ hr} F_3C \xrightarrow{S} NH_2 \xrightarrow{O-5^\circ C \ 2 \ hr} F_3C \xrightarrow{N} NH_2 \xrightarrow{O-5^\circ C \ 2 \ hr} F_3C \xrightarrow{N} NH_2 \xrightarrow{O-5^\circ C \ 2 \ hr} F_3C \xrightarrow{N} NH_2 \xrightarrow{O-5^\circ C \ 2 \ hr} F_3C \xrightarrow{N} NH_2 \xrightarrow{O-5^\circ C \ 2 \ hr} F_3C \xrightarrow{N} NH_2 \xrightarrow{O-5^\circ C \ 2 \ hr} F_3C \xrightarrow{N} NH_2 \xrightarrow{O-5^\circ C \ 2 \ hr} F_3C \xrightarrow{N} NH_2 \xrightarrow{O-5^\circ C \ 2 \ hr} F_3C \xrightarrow{N} NH_2 \xrightarrow{O-5^\circ C \ 2 \ hr} F_3C \xrightarrow{N} NH_2 \xrightarrow{O-5^\circ C \ 2 \ hr} F_3C \xrightarrow{N} NH_2 \xrightarrow{N}$$

 $Scheme - 11: Synthesis \ of \ (Z) - 5 - ((6-substituted phenyl-2 - (trifluoromethyl) imidazo \ [2,1-b][1,3,4] thiadiazol-5 - yl) methylene) thiazolidine - 2,4-diones \ (Z) - 5 - ((1,2) - 2,4-diones) thiazolidine - 2,4-diones) thiazolidine - 2,4-diones \ (Z) - 5 - ((1,2) - 2,4-diones) thiazolidine - 2,4-diones) thiazolidine - 2,4-diones \ (Z) - 5 - ((1,2) - 2,4-diones) thiazolidine - 2,4-diones) thiazolidine - 2,4-diones \ (Z) - 5 - ((1,2) - 2,4-diones) thiazolidine - 2,4-diones) thiazolidine - 2,4-diones \ (Z) - 5 - ((1,2) - 2,4-diones) thiazolidine - 2$

CONCLUSION

After brief study of existing synthesized thiazolidinedione derivatives we can conclude that the scaffold exhibit various biological activities like antimicrobial, antioxidant, anticancer, antioxidant, antiinflammatory, antitubercular. In present article we have antitubercular emphasized on activity thiazolidinediones bearing various substitutions. Substitution of alkyl /aryl groups on nitrogen exhibits potent antitubercular activity. Attachment of benzene sulfonamide to N-substituted thiazolidinedione scaffold bearing electron donating group on heterocyclic ring improved activity in comparison with unsubstituted compound. Substitution of bioactive heterocycles like pyridine, oxadiazole, benzylidene at fifth position increases the antitubercular activity against M. tuberculosis. Some derivatives bearing simultaneous substitutions at nitrogen and fifth position in scaffold exhibits remarkable antitubercular activity. From the above findings one must consider thiazolidinediones as potential antitubercular agents for development.

REFERENCES

- 1. Hulin B, McCarthy PA, Gibbs EM. The Glitazone Family of Antidiabetic Agents (Current Pharmaceutical Design), Bentham Science Publishers. 1996.
- 2. Day C. British Diabetic Association Diabetic Medicine. 16(3):179.
- 3. US patent 5330998.
- 4. Aneja DK, Lohan P, Arora S, Sharma C, Aneja KR, Prakash O. Organic and Medicinal Chemistry Letters, 2011(1):11.
- Malik N, Prasad DN, Iranian Journal of Pharmaceutical Sciences Summer. 2012, 8(3): 209.
- 6. Nastasă C, Tiperciuc B, Pârvu A, Duma M, Lonut L, Oniga O, Arch. Pharm. Chem. Life Sci. 2013: 1.
- 7. Rekha S, Shantharam U, Vineet C. International Research Journal of Pharmacy. 2011,2(9): 81
- 8. Bahare RS, Ganguly S, Choowongkomon K, Seetaha S. DARU Journal of Pharmaceutical Sciences. 2015, 23(6).
- 9. Shahnaz M, Patel KB, Ramesh B, Journal of Drug Delivery & Therapeutics. 2013, 3(6): 96.
- 10. Thakur AS, Deshmukh R, Jha AK, Sudhirkumar P. Central Nervous System Agents in Medicinal Chemistry. 2016, 16(2): 152
- Available from www.who.int/news-room/factsheets/detail/tuberculosis. (accessed on

- 09/11/2019).
- 12. Napolean AA. International Journal of PharmTech Research. 2016; 9(3): 429.
- 13. Available from https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6675365.htm. (accessed on 09/11/2019).
- 14. Srivastava AR, Bhatia R, Chawla P, Bioorganic Chemistry. 2019(89):102993.
- 15. Hauner H. Diabetes/Metabolism Research Reviews. 2002, 18: S10.
- 16. Ye J. Act Pharmaceutica Sinica B. 2011, 1(3): 137.
- 17. Yki-Järvinen H. The New England Journal of Medicine. 2004, 351: 1106.
- 18. Pattan S, Kedar M, Pattan J, Dengale S, Sanap M, Gharate U, Shinde P, Kadam S, Indian Journal of Chemistry. 2012, (51)B: 1421.
- 19. Parekh NM, Juddhawala KV. Rawal BM, Medicinal Chemistry Research. 2013, 22(6), 2737.
- 20. Shaikh FM, Patel NB, Rajani D. Indian Journal of Research in Pharmacy and Biotechnology. 2013, 1(4), 496.
- Patel NB, Purohit AC, Rajani D. International Journal of Drug Design and Discovery. 2014, 5(3): 1342
- 22. Patel NB, Khan IH. Indian Journal of Research in Pharmacy and Biotechnology. 2014, 2(1): 993.
- 23. Ponnuchamy S, Kanchithalaivan S, Kumar RR, Ali MA, Choon TS. Antimycobacterial evaluation of novel hybrid arylidene thiazolidine-2, 4-diones. Bioorganic & medicinal chemistry letters. 2014 Feb 15;24(4):1089-93.
- 24. Shaikh FM, Patel NB, Sanna G, Busonera B, La Colla P, Rajani DP. Synthesis of some new 2-amino-6-thiocyanato benzothiazole derivatives bearing 2, 4-thiazolidinediones and screening of their in vitro antimicrobial, antitubercular and antiviral activities. Medicinal Chemistry Research. 2015 Aug 1;24(8):3129-42.
- 25. Khan IH, Patel NB, Patel VM. Current Computer-Aided Drug Design. 2018, (14): 269.
- Šlachtová V, Janovská L, Brulíková L. Journal of Molecular Structure. 2019, 1183: 182.
- 27. Alegaon SG, Alagawadi KR, Sonkusare PV, Chaudhary SM, Dadwe DH, Shah AH, Bioorganic & Medicinal Chemistry Letters. 2012, 22(5):1917.